A congressional advisory commission has concluded that promising rare disease therapies are failing to reach American patients because of gaps in funding, data, regulation and manufacturing, and that the country's long-held lead in the field is eroding.
The National Security Commission on Emerging Biotechnology, a bipartisan legislative advisory body chaired by Sen. Todd Young of Indiana, released a white paper identifying four main hurdles and recommending an all-of-government approach to rare disease. Vice Chair Michelle Rozo said in a statement that emerging biotechnology now makes it possible to cure rare diseases rather than manage symptoms for life, and that what the country lacks is a national strategy to channel that innovation.
These are recommendations to Congress. They are not law, not federal policy, and not binding on any agency, which matters for how families should read the coverage.
Four Barriers the Commission Identified
The commission's framing is that the science increasingly works while the surrounding system does not.
Research investment is the first barrier. Funding for rare disease work is limited relative to the number of conditions, and the large majority of rare diseases still have no FDA-approved treatment more than four decades after the Orphan Drug Act was enacted in 1983.
Data and trial design form the second. Rare disease information sits in scattered registries, individual academic centers and disconnected health systems. The commission's rare disease white paper argues that new statistical models better suited to small populations are needed, that the FDA should standardize how it handles variability in data from small groups, and that limited patient numbers may require new trial designs and individualized standards.
Regulatory capacity is the third. The commission flagged persistent staffing shortages and knowledge gaps at the FDA that leave the agency less able to assess new technologies, noting that review teams often lack expertise in rare diseases, cell and gene therapy and data science, and that high turnover drains institutional knowledge. Thousands of FDA employees departed or were laid off over the past year, and the agency has since said it is looking to hire roughly 2,200 people.
Manufacturing constraints are the fourth. Producing a therapy for a very small patient population is a different engineering problem from mass production, and capacity for it is limited.
Two Offices It Wants Congress to Create
The commission's central structural recommendation is not new, which is part of its argument.
It points back to two proposals from its April 2025 final report: a National Biotechnology Coordination Office to align work across federal agencies and streamline regulatory structures, and a biopharmaceutical manufacturing center of excellence to improve the reliability and efficiency of production methods while engaging regulators early. Both have already been introduced as legislation, including the National Biotechnology Initiative Act of 2025, and neither has been enacted.
It also recommends that Congress urge the FDA to finalize its platform technology designation program, which allows validated data from one product to carry over to others built on the same platform. That program launched in 2024 and has had a complicated early record.
The commission situates all of this as a national security question, arguing that developers are increasingly taking work to countries including China and Australia. China's share of the drug pipeline rose sharply over the past decade, reaching 30 percent of the global drug development pipeline from about 6 percent ten years earlier.
That framing is a choice. Readers can find the identified barriers real while recognizing that the national security packaging reflects the commission's mandate.
Recommendations Are Not Law
This limitation belongs stated plainly rather than at the end.
An advisory commission produces analysis and recommendations. Congress may act on them, may act on some of them in modified form, or may do nothing. The two offices it recommends have been sitting in introduced legislation without passage, which is a useful indicator of how long this can take.
The report also does not evaluate whether any specific therapy works or should be approved. It is about the system that produces therapies, not about clinical evidence for particular products.
Some federal activity is already moving in adjacent directions. The FDA announced a framework earlier this year aimed at accelerating development of individualized therapies for ultra-rare diseases, inspired in part by the case of an infant treated with a personalized gene-editing therapy, and the commission welcomed FDA's proposed trial reforms for modernizing clinical trials and prioritizing supply chain security.
Meaning for Families Living with Rare Disease
Nothing in this report changes any patient's care, and no therapy becomes available because of it.
What families can act on is the part of the problem the report identifies as fragmented data. Enrolling in a disease-specific patient registry is free, takes little time, and is how researchers identify candidates when a trial does open. Many rare disease patient organizations maintain them, and a treating specialist can usually point to the right one.
Genetic diagnosis is the prerequisite for nearly everything else. Patients commonly report years between symptom onset and a confirmed diagnosis, and a therapy cannot be designed or matched without knowing the specific variant. Anyone with an undiagnosed condition suspected to be genetic can ask a clinician about referral to a clinical geneticist or to an undiagnosed diseases program.
ClinicalTrials.gov lists trials by condition and can be checked periodically, since rare disease trials open and close with little publicity. A specialist can assess whether any are appropriate.
Families should be cautious about clinics offering gene therapy or experimental treatments outside registered clinical trials, which operate without the safety oversight legitimate programs require. Cost and coverage questions for approved orphan drugs are worth raising early with a specialty pharmacy, since manufacturer assistance programs and foundation grants exist for many of them.
The bottom line: a bipartisan congressional advisory commission identified limited research funding, fragmented data and trial design problems, regulatory capacity gaps at the FDA, and manufacturing constraints as barriers keeping rare disease therapies from patients; its recommendations are proposals to Congress that have already been introduced without passing, and the most useful step families can take now is genetic diagnosis and registry enrollment.
Key Questions Answered
Who produced the report? The National Security Commission on Emerging Biotechnology, a bipartisan advisory body to Congress chaired by Sen. Todd Young with Michelle Rozo as vice chair. It released a white paper on rare disease therapy development.
What barriers did it identify? Limited research investment, fragmented data and trial design challenges in small populations, regulatory capacity gaps at the FDA including staffing shortages and missing expertise, and manufacturing constraints.
What did it recommend? An all-of-government approach, including a National Biotechnology Coordination Office and a biopharmaceutical manufacturing center of excellence, and urging the FDA to finalize its platform technology designation program.
Are those recommendations new? No. Both offices were proposed in the commission's April 2025 final report and have been introduced as legislation, including the National Biotechnology Initiative Act of 2025, but have not been enacted.
Does the report change federal policy? No. It contains recommendations to Congress. Establishing new offices would require legislation and appropriations.
Why frame this as national security? The commission's mandate is to assess biotechnology's national security implications. It argues developers are shifting work abroad, noting China's share of the global drug pipeline reached about 30 percent from roughly 6 percent a decade earlier.
What can families do now? Pursue genetic diagnosis through a clinical geneticist, enroll in disease-specific patient registries, and check ClinicalTrials.gov periodically with a specialist's guidance.
